Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Inclusion Criteria: * Imatinib resistant or intolerant Philadelphia chromosome positive CML in blast crisis * Imatinib resistant or intolerant Philadelphia chromosome positive CML in accelerated phase * Imatinib resistant or intolerant Philadelphia chromosome positive CML in chronic phase * CML patients who have been treated with an investigational tyrosine kinase inhibitor who otherwise meet the definition of imatinib resistance or intolerance * World Health Organization (WHO) performance status ≤ 2 Exclusion Criteria: * Cytopathologically confirmed central nervous system (CNS) infiltration * Impaired cardiac function * Use of therapeutic coumarin derivatives * Acute chronic liver or renal disease unrelated to tumor * Other uncontrolled medical conditions * Treatment with hematopoeitic colony stimulating factors * Treatment with medications that have potential to prolong the QT interval * Another malignancy currently clinically significant or requires active intervention Other protocol-defined inclusion/exclusion criteria may apply.